TY - JOUR
T1 - Evidence on continuous flow peritoneal dialysis
T2 - A review
AU - de Vries, Joost C
AU - van Gelder, Maaike K
AU - Cappelli, Gianni
AU - Bajo Rubio, Maria A
AU - Verhaar, Marianne C
AU - Gerritsen, Karin G F
N1 - Funding Information:
This study was supported by the European Union (CORDIAL, Horizon 2020 research and innovation program, grant agreement no. 945207) and by the Dutch Kidney Foundation and Dutch Ministry of Economic Affairs and Climate Policy by means of a PPP Allowance made available by the Top Sector Life Sciences & Health to stimulate public–private partnerships (DKF project code PPS08). Open access funding enabled and organized by Projekt DEAL.
Funding Information:
JV, MG, GC, MBR, and KG are involved in the clinical validation of a continuous flow peritoneal dialysis system with dialysate regeneration in cooperation with Nanodialysis B.V. (CORDIAL, Horizon 2020 research and innovation program, grant agreement no. 945207, Dutch Kidney Foundation project PPS08).
Publisher Copyright:
© 2022 The Authors. Seminars in Dialysis published by Wiley Periodicals LLC.
PY - 2022/11
Y1 - 2022/11
N2 - Clinical application of continuous flow peritoneal dialysis (CFPD) has been explored since the 1960s, but despite anticipated clinical benefits, CFPD has failed to gain a foothold in clinical practice, among others due to the typical use of two catheters (or a dual-lumen catheter) and large dialysate volumes required per treatment. Novel systems applying CFPD via the existing single-lumen catheter using rapid dialysate cycling may solve one of these hurdles. Novel on-demand peritoneal dialysate generation systems and sorbent-based peritoneal dialysate regeneration systems may considerably reduce the storage space for peritoneal dialysate and/or the required dialysate volume. This review provides an overview of current evidence on CFPD in vivo. The available (pre)clinical evidence on CFPD is limited to case reports/series with inherently nonuniform study procedures, or studies with a small sample size, short follow-up, and no hard endpoints. Small solute clearance appears to be higher in CFPD compared to conventional PD, in particular at dialysate flows ≥100 mL/min using two single-lumen catheters or a double-lumen catheter. Results of CFPD using rapid cycling via a single-lumen catheter are too preliminary to draw any conclusions. Continuous addition of glucose to dialysate with CFPD appears to be effective in reducing the maximum intraperitoneal glucose concentration while increasing ultrafiltration efficiency (mL/g absorbed glucose). Patient tolerance may be an issue since abdominal discomfort and sterile peritonitis were reported with continuous circulation of the peritoneal dialysate. Thus, well-designed clinical trials of longer duration and larger sample size, in particular applying CFPD via the existing catheter, are urgently required.
AB - Clinical application of continuous flow peritoneal dialysis (CFPD) has been explored since the 1960s, but despite anticipated clinical benefits, CFPD has failed to gain a foothold in clinical practice, among others due to the typical use of two catheters (or a dual-lumen catheter) and large dialysate volumes required per treatment. Novel systems applying CFPD via the existing single-lumen catheter using rapid dialysate cycling may solve one of these hurdles. Novel on-demand peritoneal dialysate generation systems and sorbent-based peritoneal dialysate regeneration systems may considerably reduce the storage space for peritoneal dialysate and/or the required dialysate volume. This review provides an overview of current evidence on CFPD in vivo. The available (pre)clinical evidence on CFPD is limited to case reports/series with inherently nonuniform study procedures, or studies with a small sample size, short follow-up, and no hard endpoints. Small solute clearance appears to be higher in CFPD compared to conventional PD, in particular at dialysate flows ≥100 mL/min using two single-lumen catheters or a double-lumen catheter. Results of CFPD using rapid cycling via a single-lumen catheter are too preliminary to draw any conclusions. Continuous addition of glucose to dialysate with CFPD appears to be effective in reducing the maximum intraperitoneal glucose concentration while increasing ultrafiltration efficiency (mL/g absorbed glucose). Patient tolerance may be an issue since abdominal discomfort and sterile peritonitis were reported with continuous circulation of the peritoneal dialysate. Thus, well-designed clinical trials of longer duration and larger sample size, in particular applying CFPD via the existing catheter, are urgently required.
UR - https://www.scopus.com/pages/publications/85131054159
U2 - 10.1111/sdi.13097
DO - 10.1111/sdi.13097
M3 - Review article
C2 - 35650168
SN - 0894-0959
VL - 35
SP - 481
EP - 497
JO - Seminars in Dialysis
JF - Seminars in Dialysis
IS - 6
ER -